Characteristic of persistent human papillomavirus infection in women worldwide: a meta-analysis.
Genotype
HPV
Human papillomavirus
Meta-analysis
Persistent infection
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
07
2023
accepted:
14
09
2023
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
We aimed to estimate the genotype distribution of persistent human papillomavirus (HPV) infection in females worldwide, and provided a scientific basis for the prevention strategies of cervical cancer (CC) and the development of HPV vaccines. Both English and Chinese databases were researched from the inception to July 2023. The pooled persistent HPV infection prevalence was calculated using a random effects model. The subgroup analysis was performed to explore the heterogeneity. Publication bias was evaluated using funnel plot, Egger's and Begg's test. Twenty-eight studies with 27,335 participants were included. The pooled prevalence of persistent HPV infection was 29.37% (95% CI [24.05%∼35.31%]), and the genotypes with the persistent infection prevalence were HPV16 (35.01%), HPV52 (28.19%), HPV58 (27.06%), HPV18 (25.99%), HPV33 (24.37%), HPV31 (23.35%), HPV59 (21.87%), HPV39 (19.54%), HPV68 (16.61%) and HPV45 (15.05%). The prevalence of multiple and single HPV persistent infection were 48.66% and 36.71%, respectively; the prevalence of persistent HPV infection in different age groups (<30, 30∼39, 40∼49, >50) were 29.83%, 28.39%, 22.24% and 30.22%, respectively. The follow-up time was significantly associated with heterogeneity by subgroup analysis ( Multiple infections were more likely to occur persistent HPV infection than single infection. In addition to HPV vaccination, we should emphasize the follow-up management for women under 30 and over 50 years old, those with high-risk HPV infection (HPV59, 39, 68) and multiple infections.
Identifiants
pubmed: 38025679
doi: 10.7717/peerj.16247
pii: 16247
pmc: PMC10655709
doi:
Types de publication
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16247Informations de copyright
©2023 Zhao et al.
Déclaration de conflit d'intérêts
The authors declare there are no competing interests.
Références
Sex Transm Dis. 2014 Dec;41(12):732-8
pubmed: 25581810
Oncotarget. 2017 Aug 11;8(46):81455-81461
pubmed: 29113404
Contemp Clin Trials. 2015 Nov;45(Pt A):139-45
pubmed: 26343745
Int J Mol Sci. 2021 Jun 16;22(12):
pubmed: 34208758
J Med Virol. 2020 Dec;92(12):3784-3792
pubmed: 32297986
J Natl Cancer Inst. 2008 Apr 2;100(7):513-7
pubmed: 18364507
BMC Infect Dis. 2014 Jul 16;14:395
pubmed: 25030273
Papillomavirus Res. 2019 Jun;7:45-51
pubmed: 30625379
Cancer Med. 2022 Mar;11(6):1542-1552
pubmed: 34981653
Int J Gynaecol Obstet. 2010 Sep;110(3):217-22
pubmed: 20570260
Front Oncol. 2022 May 18;12:812076
pubmed: 35692793
Int J Cancer. 2013 Jul;133(1):172-81
pubmed: 23233366
J Clin Virol. 2009 May;45(1):23-7
pubmed: 19375383
Am J Obstet Gynecol. 2008 Dec;199(6):617.e1-7
pubmed: 18799155
Int J Cancer. 2003 Sep 1;106(3):396-403
pubmed: 12845680
Int J Gynecol Pathol. 2014 Sep;33(5):531-6
pubmed: 25083972
J Infect Dis. 2008 May 15;197(10):1436-47
pubmed: 18419547
MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):918-924
pubmed: 30138307
Eur J Obstet Gynecol Reprod Biol. 2013 Jun;168(2):222-6
pubmed: 23395560
J Clin Virol. 2016 Oct;83:6-11
pubmed: 27522635
Br J Cancer. 2007 May 7;96(9):1419-24
pubmed: 17342094
Lancet Glob Health. 2019 Mar;7(3):e308-e309
pubmed: 30553650
Chin J Cancer Res. 2019 Aug;31(4):663-672
pubmed: 31564809
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2015 Oct;37(5):534-40
pubmed: 26564504
Sex Transm Dis. 2015 May;42(5):272-8
pubmed: 25868140
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
PLoS One. 2019 Jun 27;14(6):e0218762
pubmed: 31246997
Infect Genet Evol. 2020 Jan;77:104048
pubmed: 31655224
Cancer Res Treat. 2018 Jul;50(3):813-822
pubmed: 28814070
Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3044-54
pubmed: 20952561
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
PLoS One. 2020 Dec 29;15(12):e0244242
pubmed: 33373380
Lancet. 2007 Sep 8;370(9590):890-907
pubmed: 17826171
J Med Virol. 2019 Apr;91(4):698-706
pubmed: 30475384
J Infect Dis. 2007 Jun 1;195(11):1582-9
pubmed: 17471427
Mod Pathol. 2014 Dec;27(12):1559-67
pubmed: 24762548
Int J Cancer. 2008 Oct 1;123(7):1685-92
pubmed: 18623128
Obstet Gynecol. 2014 Apr;123(4):817-21
pubmed: 24785610
Ann Ig. 2018 Jul-Aug;30(4 Supple 1):28-32
pubmed: 30062377
Biomed Res Int. 2013;2013:578276
pubmed: 24298551
Gynecol Oncol. 2015 Feb;136(2):178-82
pubmed: 25579107
Exp Mol Pathol. 2015 Dec;99(3):611-6
pubmed: 26450267
Br J Cancer. 2009 Apr 7;100(7):1184-90
pubmed: 19293802
PLoS One. 2011;6(11):e27937
pubmed: 22132173
J Infect Public Health. 2021 Jan;14(1):42-49
pubmed: 33341483
Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):485-90
pubmed: 12814991
Int J Infect Dis. 2021 May;106:348-357
pubmed: 33848674
Acta Cytol. 2019;63(2):159-168
pubmed: 30870844
J Infect Dis. 2008 Oct 1;198(7):971-8
pubmed: 18694334
Int J Cancer. 2013 Sep 15;133(6):1271-85
pubmed: 22961444
Cancer. 2006 Dec 25;108(6):475-9
pubmed: 17063498
J Clin Pathol. 2005 Sep;58(9):946-50
pubmed: 16126875
BMC Infect Dis. 2020 Nov 25;20(1):889
pubmed: 33238902
BMJ Open. 2016 Aug 26;6(8):e011371
pubmed: 27566633
Vaccine. 2006 Mar 30;24 Suppl 1:S1-15
pubmed: 16406226
Phys Ther. 2009 Sep;89(9):873-80
pubmed: 19723669
JAMA Netw Open. 2021 Aug 2;4(8):e2121893
pubmed: 34424304
Int J Cancer. 2016 Jan 15;138(2):361-8
pubmed: 26238558
Br J Cancer. 2018 May;118(10):1377-1381
pubmed: 29559733
J Med Virol. 2010 Apr;82(4):616-23
pubmed: 20166190